Canadian Cancer Trials Group Bulletins


Recent Publications

Cost avoidance occurs when, because of provision of a drug therapy [drug cost avoidance (DCA)] or a pathology test [pathology cost avoidance (PCA)] during trial participation, health care payers need not pay for standard treatments or testing. The aim of this study was to estimate the total DCA and PCA for Canadian patients enrolled in relevant phase III trials conducted by the Canadian Cancer Trials Group.

The authors found that, over the study period, trials conducted by the Canadian Cancer Trials Group resulted in total cost avoidance (PCA and DCA) of approximately $7,518 per patient. Although not all trials lead to cost avoidance, such savings should be taken account when the financial impact of conducting clinical research is being considered.

Tang PA, Hay AE, O'Callaghan CJ, Mittmann N, Chambers CR, Pater JL, Leighl NB. Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada. Current Oncology 23: s7-s13, 2016.

Ho MF, Bongartz T, Liu M, Kalari KR, Goss PE, Shepherd LE, Goetz MP, Kubo M, Ingle JN, Wang L, Weinshilboum RM. Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation. Molecular Endocrinology 30: 382-98, 2016.